Next |
home / stock / blrx / blrx message board
Subject | By | Source | When |
---|---|---|---|
BioLineRx to Report First Quarter 2023 Results on | midastouch017 | investorshub | 05/17/2023 12:03:40 PM |
Philip Serlin: I would like to take a | midastouch017 | investorshub | 05/11/2023 5:17:14 PM |
1.6792+0.1692 (+11.2053%) | midastouch017 | investorshub | 05/11/2023 3:10:39 PM |
Lets go go go go... Up up and away we go. | midastouch017 | investorshub | 05/11/2023 2:03:17 PM |
Three out of four: Protlix also received marketing | midastouch017 | investorshub | 05/11/2023 12:48:56 PM |
Yes! Having some fun today. Maybe it's better | RickSanchez316 | investorshub | 05/10/2023 5:45:51 PM |
$BLRX doing quite well, don't you agree? | midastouch017 | investorshub | 05/10/2023 2:52:01 PM |
BioLine RX ($BLRX) | midastouch017 | investorshub | 05/10/2023 3:28:12 AM |
$BLRX - our next skyhigh hopes? | midastouch017 | investorshub | 05/05/2023 1:36:03 PM |
$BLRX MomentumIts now | midastouch017 | investorshub | 04/30/2023 8:08:40 PM |
great news | midastouch017 | investorshub | 04/29/2023 6:21:25 PM |
$BLRX are we finally gonna see some action | midastouch017 | investorshub | 04/29/2023 6:14:33 PM |
$BLRX news all the way baby | jcon777 | investorshub | 04/26/2023 7:57:11 AM |
BioLineRx regains Nasdaq compliance | midastouch017 | investorshub | 04/25/2023 12:11:46 PM |
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | midastouch017 | investorshub | 04/25/2023 12:00:17 PM |
Lets go go go go... Up up and away we go. | midastouch017 | investorshub | 04/25/2023 1:50:24 AM |
is it bear time? Or do we go bull? | midastouch017 | investorshub | 04/24/2023 11:19:31 PM |
Found an interesting article | jcon777 | investorshub | 04/24/2023 7:21:42 PM |
$BLRX When is this gonna take off? | midastouch017 | investorshub | 04/23/2023 2:02:29 AM |
The gaining last trade up | midastouch017 | investorshub | 04/22/2023 8:55:54 PM |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...